Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The protruding (P) domain of the Norovirus GII.4 major capsid protein VP1 is a critical structural component of the viral capsid that mediates host cell attachment and entry (Prasad et al., 1999; UniProt A0A172QPU7). It is divided into two subdomains, P1 and P2, with the P2 subdomain being the most surface-exposed and hypervariable region of the virus (Tan et al., 2008). This domain contains the binding sites for histo-blood group antigens (HBGAs), which act as essential attachment factors or co-receptors for norovirus infection (Hutson et al., 2002). Because of its accessibility and role in receptor binding, the P domain is the primary target for neutralizing antibodies and the focus of vaccine development efforts, including virus-like particle (VLP) and P-particle candidates (Takeda/HilleVax TAK-214; Vaxart VXA-NVV-104). However, the GII.4 genotype is characterized by rapid antigenic drift within the P domain, allowing the virus to escape host herd immunity and cause periodic global pandemics of acute gastroenteritis (Lindesmith et al., 2008). Therapeutic strategies targeting this domain include VLP-based vaccines and experimental monoclonal antibodies designed to block HBGA interactions (Ford-Siltz et al., 2020).
Inhibition of viral attachment to host histo-blood group antigens (HBGAs) and neutralization of the virus by blocking the P2 subdomain binding interface.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Norovirus GII.4 major capsid protein VP1 protruding domain (VP1 P domain) (VP1 P domain).